ESMO 2023

DATO-DX - where is it going?

5 year follow-up

My highlights of ESMO23 in metastatic breast cancer

Highlights in eBC

Remarkable efficacies in patients with HER2+ mBC with…

Early use of enzalutamide in advanced prostate cancer

New 3rd line therapy for RCC

The FGFR story in bladder cancer at ESMO23

Lu-PSMA leads forward

Clearing up non-clear cell RCC

Perioperativ immunotherapy for all resectable stage…

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Amivantamab as a new SoC for EGFR Exon 20…

Tarlatamab in SCLC

My highlights from ESMO 2023

Data updates for CDK4/6 inhibitors in EBC at ESMO23 -…

Anticipated updates and exciting new data for…

What is your definition of triple-negative breast…

What was the most exciting news at ESMO23?

Our guidelines are correct

5 year follow-up

Immunoncology in eBC - triple negative and more?

Prognostic score in early HR+/HER2-BC: translational…

Detailed view of nodal-negative patients

New data on neoadjuvant immunotherapy

Consolidation of data in early HR+ and triple-negative…

Preoperative checkpointinihition in ER+ disease

My highlights of ESMO23 in early breast cancer

Pembrolizumab solidifies as SOC in early-stage TNBC

Use of immunotherapy in the perioperative setting of…

Neoadjuvant IO - is their new strategy in HR+ breast…

Analysis of tumour microenvironment and…

ER-low corresponds diagnostically to ER-0 breast cancer

MonarchE - trial update

Negative EFS results from NeoTrip

HR+ study with > 20 % PCR

Carry-over effects in monarchE confirmed

Ribociclib effective in all subtypes

Metabolomics reveal differential expression of OMEGA 3…

Highlights in eBC

Nouvelles données sur l'immunothérapie néoadjuvante

Punti salienti in eBC

Studio NeoTrip: negativi i risultati

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6…

New ADC for metastatic breast cancer?

ADCs in HER2+, HER2low and TNBC - what is the future of…

Improvement of therapy outcome by app-based patient…

How to organize a molecular tumorboards in breast…

What was the most exciting news at ESMO23?

OP seems to be dispensable for super responders

DATO-DX - where is it going?

My highlights of ESMO23 in metastatic breast cancer

ADC + Immunotherapy - the BEGONIA study paradigm

T-DXd in HER2+ patients with brain metastases

Dato-DXd - new player in advanced luminal disease

Highlights in mBC

Even more new generation ADCs in breast cancer?

Benefit for SG even after intensive pretreatment

TULIP: Trastuzumab duocarmazine without OS benefit

Can surgery be spared following primary systemic…

New ADC in HR+ disease

Improved oncological therapy with the smartphone

Robust data from the monarchE

T-DXd - new standard of care for brain mets?

Abemaciclib remains consistent in 5-year follow-up

Still on track for success in HER2-low MBC

TROP2 expression as a potential mechanism of resistance…

Fulvestran better than anastrozole, but no survival…

Remarkable efficacies in patients with HER2+ mBC with…

Our guidelines are correct

Duvalumab + Dato-DXd effective

T-DXd also effective for brain metastases

HS20089 - a novel ADC is coming for TNBC

Patient-centered molecular medicine - a new approach

OP-1250 (Palezestrant) confirms the role of SIRDs after…

Punti salienti in mBC

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym…

La expresión de TROP2 como potencial mecanismo de…

T-DXd - nowy standard postępowania w przerzutach do…

HS20089 - un nuovo ADC che si affaccia sulla scenda del…

Lo studio BEGONIA nelle paziento con tumore triplo…

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei…

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par…

Should we use zoledronic acid in all ADT patients?

Targeted therapy will move forward - but more robust…

The optimal timing of RT after radical prostatectomy…

Brave New World in mCRPC

Immunotherapy in metastatic PCa

Lu-PSMA leads forward

IO therapy in metastatic prostate cancer.

Salvage radiotherapy the new standard

STAMPEDE. Bone prediction not for everyone - better…

EMBARK expands ENZA indication to PCa

Embark without fear

EMBARK - Quality of Life

Negative data for pembrolizumab in mHSCPC & mCRPC

When immunotherapy is probably not the best choice: The…

PSMAfore unleashes urooncologic opportunity

ENZA P:Trial and controversies

RADICALS RT: Trial and controversies

Osteoprotection at mHSPC

Big data and AI prediction tools

Early use of enzalutamide in advanced prostate cancer

TITAN: ultra-low PSA = best prognosis

Combination of radioligand therapy with chemotherapy…

Longterm toxicity of adjuvant RT after prostatectomy

CXCR2 inhibitor in PCa

PSMA FORE: Trial and controversies

EMBARK och livskvalitet

Immunterapi vid prostatacancer

STAMPEDE data. Skelettstärkande och riskstratifiering.

Big Data och AI för prediktion vid prostatacancer

CXCR2 hämmare och prostatacancer

Part1: New standard of care in first line urothelial…

FGFR inhibitors and ADC combinations in urothelial…

FGFR inhibitors: What is the best scenario for this…

Unique bladder delivery system of gemcitabine herolds…

Chemo-IO establishes itself in the first-line treatment…

DAD, DAD-IO

Amazing new data in bladder cancer

When the history of ADC is written: Redefining…

EV + Pembro as standard of care in first-line therapy…

New SoC in firstline bladder cancer

Στιγμιότυπα για τον καρκίνο των νεφρών και της…

Inhibidores de FGFR: Cual es el mejor escenario para…

L'histoire du FGFR dans le cancer de la vessie à…

Is de-escalating therapy ready for prime-time?

Where does the future therapy go in renal cell…

Kidney cancer highlights at ESMO23

Intermittent therapy also possible with TKIs

New 3rd line therapy for RCC

Clearing up non-clear cell RCC

Belzutifan in later lines of therapy

Belzutifan - whats next kidney cancer?

ALINA - remarkably positive DFS in early-stage ALK+…

Scene is set for inductive immunotherapy

Neoadjuvant chemo-immunotherapy new standards in early…

Big improvements in early stage and a subset of…

Circulating DNA in AEGEAN trial

My highlights from ESMO 2023

Substantial improvement in local regional NSCLC

ALINA - a new paradigm in operated NSCLC with…

Perioperativ immunotherapy for all resectable stage…

Perioperative IO: OS-benefi from KEYNOTE-671

ALINA - immediate change of practice!

Les points forts de l'ESMO 2023

Gros progrès dans les traitments medicaeux des stades…

Perioperatieve chemo-immunotherapie voor alle patienten…

ALINA - un nouveau paradigme dans cBNPC avec la fusion…

Evolving landscape of ADCs

Activating EGFR-mutation - what's coming up?

ESMO2023-impact on everyday practice!

Amivantamab upfront? MARIPOSA trial

MARIPOSA II: Trial and controversies

Treatment sequences for EGFR-mutated Patients

Does immunotherapy still have a place in EGFR-positive…

Amivantamab as a new SoC for EGFR Exon 20…

MARIPOSA: Trial and controversies

TROPION-Lung01: positive development

LIBRETO - a positive study, but was it necessary?

Big improvements in early stage and a subset of…

Changing treatment landscape in EGFR-mutated NSCLC

Brain metastases – options to improve the systemic…

Practice changing results on exon 20 insertion mNSCLC

NRG fusions: a new drugable target?

Substantial improvement in rare alterations

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

Amivantamab at progression? MARIPOSA-2 trial

Do ADCs have brain activity?

Adagrasib + pembrolizumab in patients with KRASG12C…

My highlights from ESMO 2023

PAPILLON - bringing together therapy for the 1st line

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

By unanimous decision and still the champion –…

Quelles séquences thérapeutiques pour les patients EGFR…

I miei punti salienti di ESMO 2023

Gros progrès dans les traitments medicaeux des stades…

Nieuwe standaard voor gemetastaseerd EGFR exon20…

Veränderte Behandlungslandschaft bei EGFR-mutiertem…

Heeft immunotherapie nog een plek in de behandeling van…

Amivantamab at progression? MARIPOSA-2 trial

L’amivantamab, nouveau standard de traitement pour les…

Amivantamab upfront? MARIPOSA trial

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

New hope for patients with SCLC

Tarlatamab in SCLC

Evolution of the revolution - the RUBY trial

Update on gynaecological cancers

New data on sarkomas

First data on luveltamab in multiline treatment for…

New data on H&N Cancer

Precision oncology in CUP